The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | HSCT with T-cell add-back of rivogenlecleucel in acute leukemia
Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, discusses the comparative analysis of alpha-beta T-cell and B-cell depleted (abTCD) HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) versus abTCD haplo-HSCT with T-cell add-back of rivogenlecleucel in children with high-risk acute leukemia (AL) in remission. This phase I/II trial (NCT02065869) tested the safety and efficacy of post-transplant infusion of a titrated number of donor-derived T-cells transduced with the iC9 gene in children with high-risk AL, in order to avoid GvHD. Data confirms that the infusion of donor-derived rivogenlecleucel is safe, well tolerated and improved patients non-relapse-mortality and leukemia-free survival. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
